Thoracic Aortic Aneurysm Medical Therapy
Overview
Medical therapy for patients with a thoracic aortic aneurysm includes aggressive blood pressure control targeting a goal of 130/80 mmHg for all patients, heart rate reduction with beta-adrenergic blocking agents, lipid management, and smoking cessation. For patients with heritable thoracic aortic disease (HTAD), including Marfan syndrome, Loeys-Dietz syndrome, and bicuspid aortic valve-associated aortopathy, gene-specific pharmacotherapy is a cornerstone of management. Medical therapy is continued in parallel with serial surveillance imaging and remains the primary treatment strategy until aneurysm size or growth rate reaches thresholds warranting surgical or endovascular intervention.
Medical Therapy
- 2 large bore IV needles
- Adequate airway and breathing
- Urinary output monitoring
Emergency Care
- Aggressive blood pressure and heart rate control
- Target systolic blood pressure 100 to 120 mmHg and heart rate less than 60 bpm
- IV esmolol (preferred first-line titratable agent)
- IV labetalol (combined alpha/beta blockade)
- V sodium nitroprusside (adjunct vasodilator; must not be used without concurrent beta-blocker due to reflex tachycardia)
- IV opioid analgesia for pain control as needed
- Avoid aggressive fluid resuscitation in the absence of hypotension
- Immediate cardiac surgery consultation
Medications
2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease
Medical Treatment of Patients With Thoracic Aortic Disease
| Class I
|
| 1. Stringent control of hypertension, lipid profile optimization, [[smoking cessation]], and other [[atherosclerosis]] risk-reduction measures should be instituted for all patients with [[thoracic aortic aneurysm]] not requiring immediate surgical intervention, as well as for patients who are not considered surgical or stent graft candidates. (Level of Evidence: C)"
|
Blood Pressure and Heart Rate Control
| Class I
|
| "1. [[Antihypertensive therapy]] is recommended for all patients with [[thoracic aortic disease]] to achieve a blood pressure goal of ≤130/80 mmHg, regardless of the presence of [[diabetes mellitus|diabetes]] or [[chronic kidney disease]], to reduce the risk of aortic growth, [[aortic dissection|dissection]], [[stroke]], [[myocardial infarction]], [[heart failure]], and cardiovascular death. (Level of Evidence: B)"
|
| "2. [[Beta-adrenergic blocking drug|Beta-adrenergic blocking agents]] are recommended as the preferred first-line antihypertensive drug class in patients with [[thoracic aortic aneurysm]] to reduce aortic wall stress through reduction of both blood pressure and the rate of pressure rise (dP/dt). (Level of Evidence: B)"
|
| "3. [[Beta-adrenergic blocking drug|Beta-adrenergic blocking drugs]] are recommended for all patients with [[Marfan syndrome]] and [[aortic aneurysm]] to reduce the rate of aortic dilatation unless contraindicated. (Level of Evidence: B)"
|
| "4. [[Angiotensin receptor blocker|Angiotensin receptor blockers]] are recommended for patients with [[Marfan syndrome]] and [[aortic aneurysm]] as an alternative or additive therapy to [[beta-adrenergic blocking drug|beta-adrenergic blocking agents]] to reduce the rate of aortic dilatation unless contraindicated. (Level of Evidence: B)"
|
| Class IIa
|
| "1. For patients with [[thoracic aortic aneurysm]], it is reasonable to reduce blood pressure and heart rate with [[beta-adrenergic blocking drug|beta-adrenergic blocking agents]] and/or [[angiotensin-converting enzyme inhibitor|ACE inhibitors]] or [[angiotensin receptor blocker|angiotensin receptor blockers]], titrated to the lowest tolerated levels without adverse effects. (Level of Evidence: B)"
|
| Class III (Harm)
|
| "1. [[Angiotensin-converting enzyme inhibitor|ACE inhibitors]] and [[angiotensin receptor blocker|angiotensin receptor blockers]] are contraindicated during [[pregnancy]] in patients with [[heritable thoracic aortic disease]] due to teratogenicity; [[beta-adrenergic blocking drug|beta-adrenergic blocking agents]] ([[labetalol]] or [[metoprolol]]) are the preferred antihypertensive agents in this setting. (Level of Evidence: C)"
|
Medical Management of Heritable Thoracic Aortic Disease
| Class IIa
|
| "1. In patients with [[Loeys-Dietz syndrome]] and [[aortic aneurysm]], it is reasonable to treat with [[angiotensin receptor blocker|angiotensin receptor blockers]] to reduce the rate of aortic dilatation. (Level of Evidence: C)"
|
| "2. In patients with [[bicuspid aortic valve]]-associated aortopathy and [[aortic aneurysm]], it is reasonable to treat with [[beta-adrenergic blocking drug|beta-adrenergic blocking agents]] or [[angiotensin receptor blocker|angiotensin receptor blockers]] to reduce blood pressure and slow aortic dilatation. (Level of Evidence: C)"
|
Dyslipidemia Treatment
| Class IIa
|
| "1. Treatment with a [[statin]] is reasonable for patients with atherosclerotic [[thoracic aortic aneurysm]] or aortic arch [[atheroma]] to reduce cardiovascular risk and the risk of [[stroke]]. (Level of Evidence: B)"
|
Smoking Cessation
| Class I
|
| "1. [[Smoking cessation]] and avoidance of exposure to environmental tobacco smoke at work and home are recommended for all patients with [[thoracic aortic disease]]. Follow-up, referral to special programs, and/or pharmacotherapy (including [[nicotine replacement therapy|nicotine replacement]], [[bupropion]], or [[varenicline]]) is useful, as is adopting a stepwise strategy aimed at smoking cessation (the 5 As: Ask, Advise, Assess, Assist, and Arrange). (Level of Evidence: B)"
|
Surveillance Imaging During Medical Management
| Class I
|
| "1. In patients with known [[thoracic aortic aneurysm]] managed medically, cross-sectional imaging with [[CT|CTA]] or [[MRI|MRA]] of the entire aorta is recommended at the time of initial diagnosis to establish baseline aortic dimensions using a standardized measurement technique. (Level of Evidence: B)"
|
| "2. Repeat aortic imaging is recommended at 6 months after the initial study to assess the rate of aortic growth before establishing a long-term surveillance interval. (Level of Evidence: B)"
|
| "3. Annual surveillance imaging is recommended for patients with stable [[thoracic aortic aneurysm]] to detect interval growth that may warrant surgical referral. (Level of Evidence: B)"
|
| Class IIa
|
| "1. [[MRI|MRA]] is reasonable to use in preference to [[CT|CTA]] for serial surveillance of [[thoracic aortic aneurysm]] when feasible, to minimize cumulative radiation exposure, particularly in younger patients and those with heritable aortopathies. (Level of Evidence: C)"
|
| "2. Surveillance imaging every 3 to 6 months is reasonable for patients with aortic aneurysms approaching the surgical threshold size or with a prior documented growth rate of ≥0.5 cm per year. (Level of Evidence: C)"
|
Takayasu Arteritis and Giant Cell Arteritis
| Class I
|
| "1. Initial therapy for active [[Takayasu arteritis]] and active [[giant cell arteritis]] should be [[corticosteroid|corticosteroids]] at a high dose ([[prednisone]] 40 to 60 mg daily at initiation or its equivalent) to reduce the active inflammatory state. (Level of Evidence: B)"
|
| "2. The success of treatment of patients with [[Takayasu arteritis]] and [[giant cell arteritis]] should be periodically evaluated to determine disease activity by repeated physical examination and measurement of either an [[erythrocyte sedimentation rate]] or [[C-reactive protein]] level. (Level of Evidence: B)"
|
| "3. Elective [[revascularization]] of patients with [[Takayasu arteritis]] and [[giant cell arteritis]] should be delayed until the acute inflammatory state is treated and quiescent. (Level of Evidence: B)"
|
| Class IIa
|
| "1. It is reasonable to add a steroid-sparing immunosuppressive agent (e.g., [[methotrexate]], [[azathioprine]], or [[mycophenolate mofetil]]) in patients with [[Takayasu arteritis]] receiving [[corticosteroid|corticosteroids]] who demonstrate progression of vascular disease, recurrence of constitutional symptoms, or re-elevation of inflammatory markers. (Level of Evidence: C)"
|
| Class IIb
|
| "1. In patients with [[Takayasu arteritis]] refractory to or unable to tolerate [[corticosteroid|corticosteroids]], [[TNF inhibitor|tumor necrosis factor inhibitors]] (e.g., [[infliximab]] or [[etanercept]]) or other biologic immunosuppressive agents may be considered to achieve and maintain disease remission. (Level of Evidence: C)"
|
Aortic Arch and Thoracic Aortic Atheroma and Atheroembolic Disease
| Class IIa
|
| "1. Treatment with a [[statin]] is a reasonable option for patients with aortic arch [[atheroma]] to reduce the risk of [[stroke]] and systemic [[embolism]]. (Level of Evidence: B)"
|
| Class IIb
|
| "1. [[Antiplatelet]] therapy or oral [[anticoagulation]] with [[warfarin]] ([[INR]] 2.0 to 3.0) may be considered in patients with [[stroke]] attributable to aortic arch [[atheroma]] ≥4 mm in thickness to prevent recurrent [[stroke]]. (Level of Evidence: C)"
|
References
[1]"2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 146 (24): e334–e482. doi:10.1161/CIR.0000000000001106. PMID 36322642.[1]
- ↑ "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 146 (24): e334–e482. doi:10.1161/CIR.0000000000001106. PMID 36322642.